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A B S T R A C T
Objective: To examine the impact of tissue selectivity of angiotensin-convertingenzyme (ACE)
inhibitors onmortality andmorbidity in patients following acute myocardial infarction (AMI).
Methods: A retrospective cohort study using a Medicaid claims database was conducted. Pa-
tients hospitalized for an AMI and subsequently filling a prescription for an ACE inhibitor were
followed longitudinally for the occurrence of cardiovascular-related hospitalizations and all-
causemortality. A subanalysis was also conducted to account for switching/discontinuation of
ACE inhibitor therapy. Stepwise (forward conditional) Cox-proportional hazards models were
used to analyze the effect of tissue selectivity on study outcomes.
Results: The final study sample consisted of 689 AMI and the results indicated that tissue-
selective ACE inhibitors had a protective effect against hospitalization due to stroke/transient
ischemic attack (TIA) (hazard ratio [HR]  0.265; 95% confidence interval [CI]  0.101–0.698). A
similar lower rate in hospitalizations due to heart failure was observed in the group using
tissue-selective ACE inhibitors; however, the results were not statistically significant (HR 
0.681; 95%CI 0.436–1.063). A protective effectwas also observed on the combined outcome of
hospitalization due to any cardiovascular condition (HR 0.712; 95% CI 0.536–0.945). Hospi-
talizations due to recurrentAMI, need for coronary revascularizationprocedures, andmortality
were not significantly different between patients using tissue-selective and non-tissue-selec-
tive ACE inhibitors. The completer subanalysis provided similar findings regarding the impact
of tissue selectivity on study outcomes.
Conclusion: Tissue-selective ACE inhibitors may have a protective effect against hospitaliza-
tiondue to stroke/TIAorheart failurewhencompared tonon-tissue-selectiveACE inhibitors for
patients following AMI.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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igh risk for experiencing future complications [3]. Pharmaco-
ogical agents that are generally prescribed for secondary pre-
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185V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1ention include antiplatelet agents, beta-blockers, and lipid-
owering agents. In addition to these agents, angiotensin-
onverting enzyme (ACE) inhibitors are an important class of
rugs prescribed to patients after AMI to prevent cardiac re-
odeling and to reduce overall mortality and morbidity [3].
The beneficial effect of long-term ACE inhibitor therapy
fter AMI in patients with heart failure due to left-ventricular
ysfunction has been well established through randomized
linical trials [4–7]. Results from trials, such as the Heart Out-
omes Prevention Evaluation study (HOPE) [8] and the Euro-
ean trial on reduction of cardiac events with perindopril in
table coronary artery disease (EUROPA) [9], have indicated
hat patientswith known coronary artery disease, butwithout
eart failure due to left ventricular dysfunction, benefit signif-
cantly from long-term use of ACE inhibitors. However, a sub-
equent trial designed to evaluate the clinical impact of ACE
nhibitors in patients with known coronary artery disease
Prevention of Events with ACE inhibitors [PEACE]) [10] failed
o show a beneficial effect of ACE inhibitors in such patients.
ariations in results of the PEACE study, as opposed to those
rom HOPE and EUROPA, were generally attributed to differ-
nces in baseline demographics, disease severity, and con-
omitantmedication utilization of the patients enrolled in the
hree trials. However, subsequent analyses of comparable
ub-populations across the three trials still indicated there
ere significant benefits of ACE inhibitors in the HOPE and
UROPA as opposed to no benefit in the PEACE trial [11,12].
iven the conflicting results of these trials, as well as the fact
hat three different ACE inhibitors were studied in each of the
hree trials, debate has arisen regarding the comparability of
rugs within the ACE inhibitor class in terms of their clinical
fficacy [12].
Currently, there are a total of 10 different ACE inhibitors
vailable for prescribing in the United States (ramipril,
uinapril, benazepril, trandolapril, perindopril, captopril,
nalapril, fosinopril, lisinopril, and moexipril). Most of the
linical trials evaluating the clinical efficacy of ACE inhibitors
re conducted using a single ACE inhibitor within the class,
ssuming a “class effect” of these drugs. In clinical practice,
eneralizations are made about the class effect of ACE inhib-
tors, and no specific ACE inhibitor is recommended over an-
ther for long-term treatment of patients. However, there are
onsiderable differences between the various ACE inhibitors
vailable in terms of structure, pharmacokinetics, potency,
ipophilicity, and tissue selectivity [13,14]. The most debated
ifference between ACE inhibitors is in terms of their tissue
electivity. All ACE inhibitors inhibit tissue ACE, but the level
f tissue inhibition is found to vary among different ACE in-
ibitors. The tissue selectivity of an ACE inhibitor is depen-
ent on its potency in the tissue, its binding affinity, and its
evel of tissue retention [15]. ACE inhibitors can be categorized
s tissue-selective and non-tissue-selective based on esti-
ates from literature, which account for variables such as
ipophilicity, tissue potency, tissue retentiveness, and tissue
inding affinity [16]. Ramipril, quinapril, benazepril, trandola-
ril, and perindopril are generally classified as tissue-selective
CE inhibitors; captopril, enalapril, fosinopril, lisinopril, and
oexipril are classified as non-tissue-selectiveACE inhibitors.
lthough it is thought that highly lipophilic, tissue-selective tCE inhibitors may offer greater penetration into atheroscle-
otic plaque, the clinical impact of such tissue selectivity has
ot been substantiated.
Head-to-head, randomized, prospective clinical trials com-
aring the clinical effects of ACE inhibitors with varying degrees
f tissue-selectivity have not been conducted and may not be
conomically feasible.Only twoobservational studieshavecom-
ared the use of different ACE inhibitors in patients after AMI,
nd those studies yielded conflicting results [17,18]. Both obser-
ational studies were conducted in a Canadian health-care sys-
em and had a relatively short duration of follow-up for patients
fter their index AMI episode (mean duration of follow-up
anged from 365 to 454 days). Further, the study results were
estricted to a patient population of 65 years and over. The issue
f secondary prevention afterAMI is also important in a younger
opulation because recent reports indicate that approximately
4% of patients 40 to 69 years old die within 5 years of their first
MI [1]. The need for a study of the clinical impact of ACE inhib-
tors in a younger population can also be substantiated by the
act that data from multiple trials of ACE inhibitors have indi-
ated a trend toward greater proportional mortality reduction
mong younger patients [19].
tudy Objective
heobjective of our studywas to examine the impact of the type
f ACE inhibitor (tissue-selective vs. non-tissue-selective) on
ortality and morbidity (measured as future hospitalizations
ue to cardiovascular causes) in patients with AMI.
ethods
ata source
he study was conducted using administrative claims data
rom a state Medicaid program (between January 1, 1999, and
ecember 31, 2007). In addition to recipient demographics and
ligibility information, the claims files had detailed informa-
ion specific to processed health care claims. For eachmedical
laim, the file contained fields such as International Classifi-
ation of Disease 9th edition (ICD-9) code of diagnosis, Com-
on Procedural Terminology (CPT) code for procedures and
ervices provided, Diagnostic Related Group (DRG) codes, date
f service, provider details, site of service (outpatient, inpa-
ient, or emergency room), and total amount paid. For phar-
acy claims, the file included fields such as National Drug
lassification (NDC) code, date of prescription fill, number of
ays supply for prescription, and amount paid.
tudy design
retrospective, cohort, observational design was used and
atients discharged from the hospital with either a primary or
econdary diagnosis code for AMI (ICD-9 code of 410.XX) be-
ween January 1, 2000, and December 31, 2006 were identified.
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186 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1nclusion/exclusion criteria
he study sample was limited to patients filling a prescription
or an ACE inhibitor within a 60-day period after discharge.
he study sample was also restricted to Medicaid recipients
ess than 65 years old to avoid the issue of coverage under both
edicaid and Medicare. Medicaid recipients who were part of
anaged care were not included in the study – restricting the
tudy to Medicaid patients enrolled in the fee-for-service pro-
ram. Also, patientswithout continuousMedicaid eligibility in
he 12-month period before the hospitalization episode for
MI and in the 60-day period post-discharge were excluded
rom the analysis. These exclusion criteria were used to en-
ure the availability of comprehensive health-care utilization
ata for the study sample.
The date of the first prescription filled for an ACE inhibitor
fter discharge was treated as the index date. These patients
ere then followed longitudinally to examine the incidence of
ortality and cardiovascular-related hospitalizations. The
ollow-up period terminated at the occurrence of study out-
omes (death or cardiovascular-related hospitalization de-
ending on the specific analysis), loss of eligibility inMedicaid,
nitiation of eligibility in Medicare or Medicaid managed care,
r the termination of the study period (i.e., December 31,
007). In addition to the intent-to-treat analysis, a completer
ubanalysis was also conducted that restricted the analysis to
he follow-up period during which the study patients were
lling their index ACE inhibitor prescription. The completer
ubanalysis incorporated the date of switching or discontinu-
tion of the index ACE inhibitor therapy (tissue-selective or
on-tissue-selective) as a censoring termination date in the
ollow-up period. Patientswere deemed to be switching if they
lled a prescription for a tissue-selective ACE inhibitor in the
ollow-up period after filling an index prescription for a non-
issue-selective ACE inhibitor or vice versa. ACE inhibitor ther-
py was considered discontinued if the patient ended therapy
n an ACE inhibitor and did not receive a refill within 90 days
f supply exhaustion of the last fill. The follow-up was termi-
ated on the date of the switch or the date that coincidedwith
0 days after supply exhaustion.
easurement of variables
ain independent variable
he main independent variable was the type of ACE inhibitor
nitiated (tissue-selective vs. non-tissue-selective) within 60
ays after hospital discharge involving an AMI. Ramipril,
uinapril, benazepril, trandolapril, and perindopril were clas-
ified as tissue-selective ACE inhibitors; captopril, enalapril,
osinopril, lisinopril, and moexipril were classified as non-tis-
ue-selective ACE inhibitors.
ependent variables
he main dependent variables were all-cause mortality and
ospitalization due to cardiovascular causes.
ll-cause mortality. All-cause mortality was defined as epi-
odes of death in the cohort of patients and was identified
rom patient-eligibility records. iospitalizations due to cardiovascular causes. Cardiovascular-
elated hospitalizations were defined as events during the fol-
ow-up period resulting in hospitalization with a primary diag-
osis code for stroke/transient ischemic attack (TIA); AMI; heart
ailure; or a coronary revascularization procedure, such as coro-
ary artery bypass graft (CABG) or percutaneous transluminal
oronary angioplasty (PTCA). In addition to these individual out-
omes, a grouping variable that captured the presence of a hos-
italization due to any of the cardiovascular outcomes (stroke/
IA, AMI, heart failure, or CABG/PTCA) was created.
ontrol variables
he following baseline demographic and clinical characteris-
ics were computed and used as control variables in a multi-
ariate framework.
emographics. The demographic control variables in themul-
ivariate analysis included patient age at discharge, gender,
ype of Medicaid enrollment (traditional vs. case manage-
ent), race, and year of discharge (based on the reference AMI
ospitalization).
o-morbidity. The Charlson co-morbidity index (Romano ver-
ion) [20] was computed as an index of comorbidity. In addi-
ion, specific comorbid conditions such as diabetes, malig-
ancy, asthma, chronic obstructive pulmonary disease
COPD), depression, and chronic renal failure were identified.
hese variables were created using medical (outpatient/inpa-
ient) claims data in the 12-month period prior to the admis-
ion date and the inpatient claims during the hospitalization
or AMI.
resence of cardiovascular conditions. Claims data from the
ame time frame were used to identify specific comorbid car-
iovascular conditions such as hypertension, hyperlipidemia,
eripheral vascular disease, stroke/TIA, other cerebrovascular
iseases, cardiac arrhythmias, heart failure, cardiopulmonary
isorders, and angina.
oncomitant medication use. Prescriptions for beta-blockers,
ngiotensin II receptor blockers (ARBs), nitrates, aspirin, di-
retics, calcium-channel blockers, antiplatelet agents, antico-
gulants, non-steroidal anti-inflammatory drugs (NSAIDs),
tatins, and other lipid-lowering agents in the 60-day period
fter discharge were assessed.
isease severity. Length of stay in the hospital during the AMI
pisode, prior AMI (in the 12-month pre-period), type of AMI
iagnosis in the index hospital stay (primary or secondary),
eed for coronary revascularization procedures such as CABG
r PTCA, and dose of the initial ACE inhibitor prescription after
ischarge were determined.
tatistical analyses
he baseline demographic and clinical characteristics of pa-
ients using tissue-selective versus non-tissue-selective ACE
nhibitors were compared using a chi-square or independent
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187V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1amples Student t test. Stepwise (forward-conditional) Cox-
roportional hazards models were used to analyze the effect
f tissue-selectivity on study outcomes after controlling for
ovariates. The assumption of proportional hazards was
ested for all Cox-proportional hazard models. All the statisti-
al analyses were conducted using STATA 9.0 (STATA Corp.,
ollege Station, TX, USA) and SPSS 16.0 (SPSS Inc., Chicago, IL,
SA). Statistical significance was set at 0.05 (two-sided).
esults
total of 8344 patients were identified as being hospitalized
ith a primary or secondary diagnosis for AMI between Janu-
ry 1, 2000, and December 31, 2006. After accounting for the
nclusion/exclusion criteria, the final study sample consisted
f 689 patients filling a prescription for an ACE inhibitor fol-
owing AMI (Table 1).
aseline characteristics
total of 689 AMI patients who were initiated on an ACE in-
ibitor within the 60-day post-period were identified (tissue-
elective ACE inhibitor  242; non-tissue-selective ACE inhib-
tor  447). The most commonly prescribed ACE inhibitors
ere lisinopril (n284; 41.2%), ramipril (n132; 19.2%), and
nalapril (n108; 15.7%). The final sample had a mean age of
3 years old ( 8.10 years), consisted of 59.7% females, andwas
rimarily white (n569; 82.6%). Nearly half the patients had a
iagnosis of heart failure (n319; 46.3%) and 14.5% of the pa-
ients had a prior diagnosis of AMI in the 12-month period
rior to our reference AMI hospitalization episode.
Overall, the two groups of patients were not significantly dif-
erent in terms of baseline demographics, comorbid conditions,
elated cardiovascular conditions, and disease severity (with the
xception of year of discharge); however, there were significant
ifferences in theuseof concomitantmedications. Specifically, a
ignificantly lower proportion of patients using tissue-selective
CE inhibitors were prescribed diuretics when compared to
hose using non-tissue-selective ACE inhibitors (43.0% vs. 53.9%;
Table 1 – Sample selection.
Criteria
Patients with a hospitalization for AMI between January 1, 2000, and
2006
Exclusion of patients eligible for Medicare, Medicaid managed care, a
or 65 years of age
Requisite of continuous eligibility in the 12-month period prior to ind
Patients remaining after deleting those without comprehensive Med
more than the 60-day period post-admission (also excludes patien
years old in the 2-month period post-discharge)
Patients filling a prescription for an ACE inhibitor in the 60-day perio
(index AMI hospitalization)
Patients remaining after excluding those with a hospitalization for st
heart failure, or CABG/PTCA before the index ACE inhibitor prescri
(Final sample)coronary angioplasty; TIA, transient ischemic attack. 0.006). Also, patients using tissue-selective ACE inhibitors
ad a significantly higher use of non-statin lipid lowering agents
11.6%) when compared to patients using non-tissue-selective
CE inhibitors (6.5%) (P0.029). Significantdifferenceswerealso
bserved in terms of dose of initial ACE inhibitor prescription,
ith tissue-selective ACE inhibitors being prescribed at higher
oses when compared to non-tissue-selective ACE inhibitors (P
0.001) (Table 2).
mpact of tissue selectivity on mortality and morbidity
he mean follow-up period for the intent-to-treat analysis
anged from 701 to 974 days. The intent-to-treat analyses in-
icated that tissue-selective ACE inhibitors had a protective
ffect against the occurrence of hospitalization for stroke/TIA
hazard ratio [HR] 0.265; 95% confidence interval [CI] 0.101
o 0.698). A similar lower rate in hospitalizations due to heart
ailure was observed in the group using tissue-selective ACE
nhibitors; however, the results were not statistically signifi-
ant (HR0.681; 95% CI 0.436–1.063). The other cardiovascu-
ar outcomes, such as subsequent hospitalizations due to re-
urrent AMI or need for CABG/PTCA were not significantly
ifferent between the tissue-selective and non-tissue-selec-
ive groups (Table 3). A grouping variable that captured the
resence of a hospitalization due to any of the cardiovascular
utcomes (stroke/TIA, AMI, heart failure, or CABG/PTCA) was
reated. Survival analysis indicated that patients prescribed
issue-selective ACE inhibitors were less likely to be hospital-
zed for any cardiovascular cause when compared to those
rescribed a non-tissue-selective ACE inhibitor (HR0.712;
5% CI0.536–0.945). All-cause mortality was not found to be
ignificantly different between the two groups (Table 3).
In the subanalysis that incorporated the time to switching or
iscontinuation of ACE inhibitors, the mean follow-up period
anged from 309 to 360 days. Results of the completer subanaly-
is were similar to those obtained by the initial intent-to-treat
nalysis (Table 4). Patients using tissue-selective ACE inhibitors
ad significantly fewer hospitalizations due to heart failure
hen compared to patients using non-tissue-selective ACE in-
ibitors (HR 0.317; 95% CI  0.134–0.750). Although there was
Number (%) of
patients dropped
Number (%) of
patients remaining
mber 31, — 8344 (100)
ho are 18 4624 (55.4) 3720 (44.6)
ospitalization 2208 (59.4) 1512 (40.6)
eligibility for
o turned 65
214 (14.2) 1298 (85.8)
t-admission 844 (65.0) 724 (35.0)
TIA, AMI,
fill date
35 (4.8) 689Dece
nd w
ex h
icaid
ts wh
d pos
roke/
ption
ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal
188 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1Table 2 – Baseline characteristics of the study sample.
Non-tissue selective
ACE (n  447)
Tissue-selective
ACE (n  242)
Test statistic Significance
(P value)
Demographics
Age (in years) 53.26  7.77* 52.70  8.65* t  0.870 0.385
Males 40.3% (n  180) 40.5% (n  98) 2  0.003 0.954
Whites 82.1% (n  367) 83.5% (n  202) 2  0.204 0.651
Traditional Medicaid 60.6% (n  271) 60.7% (n  147) 2  0.001 0.976
Year of index AMI hospitalization
-2000 12.5% (n  56) 12.0% (n  29) 2  19.53 0.003†
-2001 11.2% (n  50) 15.3% (n  37)
-2002 12.8% (n  57) 21.5% (n  52)
-2003 16.8% (n  75) 10.3% (n  25)
-2004 17.7% (n  79) 12.4% (n  30)
-2005 13.0% (n  58) 16.1% (n  39)
-2006 16.1% (n  72) 12.4% (n  30)
Comorbid conditions
Charlson comorbidity index (Romano) 4.17  2.41* 4.12  2.36* t  0.251 0.802
Presence of comorbid conditions
-Asthma 16.8% (n  5) 21.5% (n  52) 2  2.316 0.128
-Cancer 6.3% (n  28) 5.8% (n  14) 2  0.063 0.802
-Chronic renal failure 9.8% (n  44) 9.9% (n  24) 2  0.001 0.975
-COPD 46.3% (n  207) 47.1% (n  114) 2  0.040 0.841
-Depression 37.8% (n  169) 33.9% (n  82) 2  1.044 0.307
-Diabetes 53.0% (n  237) 53.7% (n  130) 2  0.031 0.861
Cardiovascular conditions
-Angina 50.3% (n  225) 52.9% (n  128) 2  0.411 0.522
-Heart failure 46.1% (n  206) 46.7% (n  113) 2  0.023 0.878
-Cerebrovascular conditions 22.1% (n  99) 18.6% (n  45) 2  1.199 0.274
-Stroke/TIA 9.8% (n  44) 9.1% (n  22) 2  0.103 0.749
-Cardiac arrhythmias 41.8% (n  187) 41.7% (n  101) 2  0.001 0.980
-Peripheral vascular disease 21.7% (n  97) 20.7% (n  50) 2  0.101 0.751
-Cardiopulmonary disease 7.6% (n  34) 6.6% (n  16) 2  0.231 0.631
-Hypertension 77.0% (n  344) 77.7% (n  188) 2  0.047 0.828
-Hyperlipidemia 45.9% (n  205) 50.0% (n  121) 2  1.079 0.299
Concomitant medications
-ARBs 2.7% (n  12) 4.5% (n  11) 2  1.685 0.194
-Beta-blockers 77.2% (n  345) 81.4% (n  197) 2  1.669 0.196
-Calcium-channel blockers 20.8% (n  93) 26.9% (n  65) 2  3.256 0.071
-Statins 65.8% (n  294) 71.9% (n  174) 2  2.707 0.100
-Other lipid-lowering drugs 6.5% (n  29) 11.6% (n  28) 2  5.343 0.021†
-Diuretics 53.9% (n  241) 43.0% (n  104) 2  7.516 0.006†
-Nitrates 60.2% (n  269) 63.6% (n  154) 2  0.792 0.374
-Aspirin 38.0% (n  170) 35.1% (n  85) 2  0.569 0.451
-NSAIDs 18.6% (n  83) 20.7% (n  50) 2  0.441 0.506
-Anticoagulants 11.0% (n  49) 11.6% (n  28) 2  0.059 0.809
-Antiplatelet agents 61.3% (n  274) 63.2% (n  153) 2  0.247 0.619
Disease severity
Procedures performed during index hospitalization
-CABG 3.6% (n  16) 5.0% (n  12) 2  2.405 0.300
-PTCA 32.9% (n  147) 37.2% (n  90)
Primary diagnosis for AMI during the index hospitalization 76.3% (n  341) 81.4% (n  197) 2  2.404 0.121
Length of stay during the index AMI hospitalization 5.94  6.53* 6.33  6.75* t  0.753 0.452
Prior AMI diagnosis 15.2% (n  68) 13.2% (n  32) 2  0.501 0.479
Dose of index ACE inhibitor prescription
-Low dose 27.5% (n  123) 13.6% (n  33) 2  19.316 <0.001†
-Standard dose 62.9% (n  281) 71.1% (n  172)
-High dose 9.6% (n  43) 15.3% (n  37)
ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; ARBs, angiotensin II receptor blockers; CABG, coronary artery bypass
graft; 2 chi-square test; COPD, chronic obstructive pulmonary disease; NSAIDs, non-steroidal anti-inflammatory drugs; PTCA, percutaneous
transluminal coronary angioplasty; t  independent sample Student t test; TIA, transient ischemic attack.
* Mean  standard deviation.
† Significance at the 0.05 level.
a
h
n
h
a
c
e
r
r
t
t
R
c
b
189V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1n indication of a protective effect, the hazard ratios for future
ospitalizations due to stroke/TIA failed to reach statistical sig-
ificance (HR  0.247; 95% CI 0.055–1.120). The proportional
azards assumption was violated for the Cox-proportional haz-
rds model estimating the impact of tissue-selectivity on the
ombined metric of any cardiovascular outcomes. A further
valuation of the hazard curves indicated two distinct time pe-
Table 3 – Survival analysis results to examine the impact o
mortality (Intent-to-treat analysis).
Stroke/TIA AMI Heart
Tissue-selective
ACE
inhibitors
(Reference:
non-tissue-
selective ACE
inhibitors)
0.265* (0.101–0.698) 0.972 (0.631–1.498) 0.681 (0.43
Numbers
reported as
adjusted HR
(95% CI)
(number of events
 34/689; tissue
selective  5/242;
non-tissue
selective  29/
447)
(number of events
 95/689; tissue
selective  31/
242; non-tissue-
selective  64/
447)
(number o
 103/6
selectiv
27/242;
tissue s
76/447)
The survival models were stepwise regression models (forward condi
Age at discharge, gender, type ofMedicaid enrollment (traditional vs.
co-morbidity index (Romano version), specific co-morbid conditions
disease, depression, and chronic renal failure; Presence of cardiovascu
stroke/TIA, other CVD, cardiac arrhythmias, heart failure, cardiopulm
beta-blockers, angiotensin II receptor blockers, nitrates, aspirin, di
NSAIDs, statins, and other lipid-lowering agents; Disease severity–Le
12-month pre-period), type of AMI diagnosis in the index hospital sta
such as CABG or PTCA, and dose of the initial ACE inhibitor prescript
ACE, angiotensin-converting enzyme; AMI, acute myocardial infarc
cardiovascular disease; HR, hazard ratio; NSAIDs, non-steroidal anti
plasty; TIA, transient ischemic attack.
* Significance at the 0.05 level.
Table 4 – Survival analysis results to examine the impact o
mortality (completer analysis).
Stroke/TIA AMI Heart failure
Tissue-selective
ACE
inhibitors
(Reference:
non-tissue-
selective ACE
inhibitors)
0.247 (0.055–1.120) 0.801 (0.406–1.577) 0.317 (0.134–0.75
Numbers
reported as
adjusted HR
(95% CI)
(number of events 
18/689; tissue
selective  2/242;
non-tissue selective
 16/447)
(number of events
 46/689; tissue
selective  12/
242; non-tissue
selective  34/
447)
(number of even
 48/689; tissu
selective  6/
242; non-tissu
selective  42
447)
The survival models were stepwise regression models (forward cond
Demographics–Age at discharge, gender, type ofMedicaid enrollment (t
The Charlson co-morbidity index (Romano version), specific co-morb
pulmonary disease, depression, and chronic renal failure; Presence of c
disease, stroke/TIA, other CVD, cardiac arrhythmias, heart failure, car
tions for beta-blockers, angiotensin II receptor blockers, nitrates, asp
lants, NSAIDs, statins, and other lipid-lowering agents; Disease severit
12-month preperiod), type of AMI diagnosis in the index hospital sta
such as CABG or PTCA, and dose of the initial ACE inhibitor prescript
ACE, angiotensin-converting enzyme; AMI, acute myocardial infarc
cardiovascular disease; HR, hazard ratio; NSAIDs, non-steroidal anti
plasty; TIA, transient ischemic attack.
* Significance at the 0.05 level.iodswithinwhich thehazardswere proportional (follow-uppe-
iod 365 days and follow-up period 365 days); hence, an ex-
ended Cox-proportional hazards model was used to evaluate
he impactof tissue selectivity in these twodistinct timeperiods.
esults of the extended Cox-proportional hazards model indi-
ated that tissue selectivity hadno significant effect on the com-
ined metric of cardiovascular outcomes in the first 365 days of
sue selectivity of ACE inhibitors on morbidity and
CABG/PTCA Any CVD outcome All-cause mortality
3) 0.868 (0.562–1.341) 0.712* (0.536–0.945) 0.990 (0.693–1.416)
ts
sue
ve 
(number of events
 94/689; tissue
selective  30/
242; non-tissue
selective  64/
447)
(number of events 
248/689; tissue
selective  76/
242; non-tissue
selective  172/
447)
(number of events
 145/689; tissue
selective  46/
242; non-tissue
selective  99/
447)
l) with the following variables entered into the model: Demographics–
anagement), race, and year of discharge; Co-morbidity–The Charlson
as diabetes, malignancy, asthma, chronic obstructive pulmonary
nditions–hypertension, hyperlipidemia, peripheral vascular disease,
y disorders, and angina; Concomitant medication use–Prescriptions for
cs, calcium-channel blockers, anti-platelet agents, anticoagulants,
of stay in the hospital during the AMI episode, prior AMI (in the
mary or secondary), need for coronary revascularization procedures
fter discharge.
CABG, coronary artery bypass graft; CI, confidence interval; CVD,
mmatory drugs; PTCA, percutaneous transluminal coronary angio-
sue selectivity of ACE inhibitors on morbidity and
CABG/PTCA Any CVD outcome All-cause mortality
979 (0.540–1.775) Within the
initial 365
days
1.357 (0.839–2.195) 0.796 (0.357–1.772)
After 365 days
of follow-up
0.139 (0.051–0.379)*
umber of events
 50/689; tissue
selective  16/
242; non-tissue
selective  34/
447)
(number of events
 126/689;
tissue selective
 27/242; non-
tissue selective
 99/447)
(number of events 
34/689; tissue
selective  8/242;
non-tissue
selective  26/447)
l) with the following variables entered into the model:
onal vs. casemanagement), race, and year of discharge;Co-morbidity–
nditions such as diabetes, malignancy, asthma, chronic obstructive
ascular conditions–hypertension, hyperlipidemia, peripheral vascular
lmonary disorders, and angina; Concomitant medication use–Prescrip-
iuretics, calcium-channel blockers, anti-platelet agents, anticoagu-
gth of stay in the hospital during the AMI episode, prior AMI (in the
mary or secondary), need for coronary revascularization procedures
fter discharge.
CABG, coronary artery bypass graft; CI, confidence interval; CVD,
mmatory drugs; PTCA, percutaneous transluminal coronary angio-f tis
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190 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1he follow-up period; however, patients using tissue-selective
CE inhibitors had a significantly lower hazard when compared
o patients using non-tissue-selective ACE inhibitors in the fol-
ow-up period after 365 days (HR0.139; 95% CI 0.051–0.379).
iscussion
he results of the study indicated that tissue-selective ACE in-
ibitors may have a protective effect against hospitalization for
troke/TIA and heart failure when compared to non-tissue-se-
ective ACE inhibitors. The combined outcome of the occurrence
f hospitalization for any cardiovascular eventwas also found to
e significantly lower for patients using tissue-selective ACE in-
ibitors. None of the other outcomes (AMI, CABG/PTCA, or all-
ause mortality) was different between the two groups.
There have been few studies that have compared ACE inhib-
torsagainst eachother in termsofmortalityandmorbiditypost-
MI. Pilote et al. [17] conducted a retrospective cohort study of
CE inhibitor use in elderly patients incurring anAMI inQuebec,
anada. The results of the study indicated that patients using
amipril had significantly lower mortality rates (compared to
hose using fosinopril, captopril, or enalapril) and significantly
ower rates of repeat hospitalizations for heart failure, when
ompared to fosinopril and enalapril. No differences between
CE inhibitors were observed in terms of recurrent AMI. A sub-
equent studybyTuet al. [18], conducted inOntario, Canada, did
ot detect a significant difference between any of the ACE inhib-
tors in terms of reducing mortality or recurrent AMI.
Our study results were similar to the study by Pilote et al. [17]
n terms of the impact of ACE inhibitors on hospitalizations for
eart failure. Pilote et al. demonstrated a protective effect of
amipril (a tissue-selective ACE inhibitor) when compared to
osinopril or enalapril (both non-tissue-selective agents). How-
ver, our study, unlike the Pilote et al. [17] study, failed to detect
beneficial effect of tissue-selective ACE inhibitor on mortality.
his discrepancy in mortality results could be due to an older
ohort in the Pilote study (65 years of age), which was com-
ared to the cohort in our study (restricted to patients65 years
f age). Our study results in terms of impact of ACE inhibitors on
ecurrent AMI were consistent with findings from both Pilote et
l. [17] and Tu et al. [18]. That is, no significant differences be-
ween ACE inhibitors on the rates of recurrent AMI were ob-
erved.
Our study cohort (except the age criteria) was similar to the
ilote et al. [17] study; it included patients with known heart
ailure, prior AMI, and previous use of ACE inhibitors. The study
y Tu et al. [18] used strict inclusion criteria and excluded pa-
ients with heart failure, prior AMI, and those with use of ACE
nhibitor therapy before the index AMI hospitalization. Unfortu-
ately, the relatively small sample size inour studypreventedus
rom replicating results for a cohort similar to the study by Tu
tal. [18]. In termsof strengths, the intent-to-treatanalysisofour
tudy had a longer mean follow-up duration of 701 to 974 days
hencomparedwith follow-updurations ranging from365days
o 454 days in the previously published studies. Also, our study
xamined additional outcomes such as hospitalizations due to
troke/TIAand theneed forCABG/PTCA thatwerenot examined
n other studies. eResults of our study are subject to certain limitations. The
tudy resultswere limited to enrollees less than65years oldwho
ere not part of managed care in a state Medicaid Program.
ence, they may not be generalizable to other state Medicaid
rograms or populations. Some of the study limitations such as
nder-diagnosis andmisdiagnosis of medical conditions are in-
erent in investigations using administrative claimsdata. Use of
CE inhibitorswas based on refill information fromprescription
laims data. The study assumes that the prescriptions filled by
atients are appropriately used. Refill information from claims
ata may not be considered the most accurate and reliable; but
everal studies have found significant associations between re-
ll information and methods such as self-report, pill count, or
edication diary [21,22]. Also, prescription utilization informa-
ion during the hospitalization episode for AMI was not avail-
ble, thus preventing statistical adjustment for differences in
cute pharmacological interventions adopted during hospital-
zation.
A major limitation of the study was the limited sample size.
fter application of the predefined exclusion criteria, the final
tudy samplewas restricted to a total of 689 patients. This small
ample size prevented detailed subanalysis based on individual
CE inhibitor therapy. This is an important factor, because the
ategorization of tissue-selective and non-tissue-selective ACE
nhibitors is debatable and based on crude estimates from liter-
ture. However, restricting the analysis to the most commonly
rescribed ACE inhibitors in our study and those with relatively
eliable estimates of tissue selectivity (tissue-selective: ramipril;
on-tissue-selective: lisinopril and enalapril) provided similar
esults (datanot reported).Also, the small sample sizeprevented
he use of amore restricted cohort of AMI patients (for example,
hose without heart failure and previous AMI) and a stricter in-
lusion criteria for identification of AMI hospitalization episodes
only primary diagnosis of AMI, diagnosis codes with fifth sub-
igit of 1 [410.x1], and hospitalization episodes of longer than 3
ays). However, these criteria were used as control variables in
he multivariate framework and were not found to differ signif-
cantly between the two comparison groups.
Mortality and hospitalizations due to cardiovascular compli-
ations can be greatly affected by presence of concomitantmed-
cations andby comorbid conditions and cardiovascular risk fac-
ors. With respect to concomitant medication use, significantly
ewer patients in the tissue-selective ACE inhibitor group were
lso taking diuretics. Given the established beneficial effects of
iuretic therapy in the treatment of high-risk hypertensive pa-
ients [23], it is possible that this difference in diuretic use may
ave had an impact on the outcomes of our study; the beneficial
ffects observed in the tissue-selective ACE inhibitor groupmay
ave been greater had diuretic use been similar among the
roups. This studywasalso limitedby the lackof data onparam-
ters such as smoking status, body mass index, blood pressure
eadings, lipidpanel results, andejection fractions.Although the
eneficial effects exhibited by ACE inhibitors in terms of cardio-
ascular risk reduction have been described as being indepen-
ent of blood pressure–lowering capability, it is well established
hat blood pressure reduction alone can reduce cardiovascular
isk. In the absence of blood pressure recordings, the degree of
lood pressure control within our study population cannot be
stimated. Further, in contrast to the above statement regarding
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191V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 8 4 – 1 9 1iuretic use, it is possible that lower diuretic use in the tissue-
elective group could indicate less severe (i.e., less symptomatic)
eart failure. However, in the absence of ventricular ejection
raction estimates and New York Heart Association functional
lassification estimates, heart failure severity is difficult to esti-
ate within our patient population and it is, therefore, unclear
ow this should be interpreted in the context of our study. In our
tudy, proxy variables available in an administrative claimsdata
ere used and amultivariate analytical framework was used to
ontrol for differences in baseline comorbid conditions, severity,
nd concomitant medication use. Although lack of clinical pa-
ameters is a major limitation, risk models for mortality in pa-
ients with AMI from administrative claims data and clinical
ata from medical records have been shown to be comparable
24].
onclusion
hen prescribing ACE inhibitors for secondary prevention
f recurrent AMI and other cardiovascular-related events in
atients recently experiencing AMI, physicians practicing
n the United States have a total of ten different agents from
hich to choose within the ACE inhibitor class. Varying
harmacologic, pharmacokinetic, and structural character-
stics could suggest that one ACE inhibitor may be better
han another. The results of this study indicated that tissue-
elective ACE inhibitors may have a greater protective effect
gainst the occurrence of hospitalization for stroke/TIA and
eart failure when prescribed for patients following AMI,
hen compared to non-tissue-selective ACE inhibitors. Fu-
ure studies focusing exclusively on the impact of tissue-
elective ACE inhibitors in a larger patient population (not
estricted to those patients who have experienced AMI) on
he occurrence of stroke/TIA and hospitalization for heart
ailure need to be conducted.
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